March 21, 2018 10:03 AM EDTUpdated 10:51 AM

Proteostasis pulls stock offering following Kerrisdale short report; Cidara issues supplemental PhII rezafungin data

John Carroll

Editor & Founder

→ Hours after the company came under assault by the hit squad at Kerrisdale Capital, Proteostasis Therapeutics $PTI yanked a planned offering of …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Proteostasis pulls stock offering following Kerrisdale short report; Cidara issues supplemental PhII rezafungin data

John Carroll

Editor & Founder

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

CBER's deputy director departs as staff shakeup continues

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

FDA approves first drug to treat ultra-rare lipid storage disease

Will CRISPR matter?

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

Pro­teosta­sis pulls stock of­fer­ing fol­low­ing Ker­ris­dale short re­port; Cidara is­sues sup­ple­men­tal PhII reza­fun­gin da­ta

Editor & Founder

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Proteostasis pulls stock offering following Kerrisdale short report; Cidara issues supplemental PhII rezafungin data